Premium
New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections
Author(s) -
De Clercq Erik
Publication year - 2019
Publication title -
chemistry – an asian journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.18
H-Index - 106
eISSN - 1861-471X
pISSN - 1861-4728
DOI - 10.1002/asia.201900841
Subject(s) - nucleoside , guanine , cytosine , phosphoramidate , favipiravir , virology , nucleoside analogue , biology , virus , biochemistry , medicine , nucleotide , dna , disease , pathology , covid-19 , infectious disease (medical specialty) , gene
Eight different compounds, all nucleoside analogues, could presently be considered as potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic fever virus (HFV) infections. They can be considered as either ( i ) adenine analogues (3‐deazaneplanocin A, galidesivir, GS‐6620 and remdesivir) or ( ii ) guanine analogues containing the carboxamide entity (ribavirin, EICAR, pyrazofurin and favipiravir). All eight owe their mechanism of action to hydrogen bonded base pairing with either ( i ) uracil or ( ii ) cytosine. Four out of the eight compounds (galidesivir, GS‐6620, remdesivir and pyrazofurin) are C‐nucleosides, and two of them (GS‐6620, remdesivir) also contain a phosphoramidate part. The C‐nucleoside and phosphoramidate (and for the adenine analogues the 1′‐cyano group as well) may be considered as essential attributes for their antiviral activity.